Apmonia Therapeutics will receive €2.5 million in funding and €7 million in equity investment from the European Innovation Council (EIC) as a winner of the EIC Accelerator program.
This major financial support, provided through the European Horizon Europe program, will enable Apmonia Therapeutics to carry out clinical operations in Europe, while strengthening its portfolio of products for various forms of cancer.
MATWIN has supported this project from the very beginning, even at the academic stage! Very promising signal, the project was awarded by the international council of MATWIN in 2023 as “Best disruptive science”
Access the press release: https://apmonia-therapeutics.com/index.php/2024/07/16/apmonia-therapeutics-to-receive-e2-5m-grant-and-e7m-equity-investment-from-the-european-innovation-council-eic-as-a-laureate-of-the-eic-accelerator-program/
